Health Care & Life Sciences » Biotechnology | Seattle Genetics Inc.

Seattle Genetics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
374,267.00
313,413.00
649,651.00
588,986.00
413,171.00
411
Total Accounts Receivable
30,099.00
39,248.00
52,930.00
61,928.00
84,774.00
146
Inventories
27,073.00
43,451.00
56,963.00
68,124.00
59,978.00
53
Other Current Assets
5,817.00
11,874.00
11,515.00
15,610.00
19,138.00
43
Total Current Assets
437,256.00
407,986.00
771,059.00
734,648.00
577,061.00
654
Net Property, Plant & Equipment
40,787.00
46,129.00
49,598.00
62,870.00
103,756.00
104
Total Investments and Advances
-
-
-
34,988.00
193,358.00
163
Intangible Assets
3,849.00
3,078.00
-
1,535.00
764.00
575
Other Assets
2,006.00
1,772.00
11,378.00
4,355.00
3,010.00
8
Total Assets
483,898.00
458,965.00
895,095.00
838,396.00
877,949.00
1,503
Accounts Payable
13,407.00
17,245.00
88,031.00
90,999.00
94,196.00
Other Current Liabilities
85,791.00
108,648.00
46,235.00
57,517.00
72,933.00
Total Current Liabilities
99,198.00
125,893.00
134,266.00
148,516.00
167,129.00
Other Liabilities
154,515.00
122,238.00
74,918.00
55,793.00
33,251.00
Total Liabilities
253,713.00
248,131.00
209,184.00
204,309.00
200,380.00
Common Equity (Total)
230,185.00
210,834.00
685,911.00
634,087.00
677,569.00
Total Shareholders' Equity
230,185.00
210,834.00
685,911.00
634,087.00
677,569.00
Total Equity
230,185.00
210,834.00
685,911.00
634,087.00
677,569.00
Liabilities & Shareholders' Equity
483,898.00
458,965.00
895,095.00
838,396.00
877,949.00

About Seattle Genetics

View Profile
Address
21823 30th Drive SE
Bothell Washington 98021
United States
Employees -
Website http://www.seattlegenetics.com
Updated 07/08/2019
Seattle Genetics, Inc. engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product ADCETRIS is an antibody-drug encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell lymphoma, or sALCL, and for certain types of cutaneous T-cell lymphoma, or CTCL. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers.